Phospholipase D2 mediates signaling by ATPase class I type 8B membrane 1

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 379-385

  Chen, Frank ^a   Ghosh, Ayantika ^a   Shneider, Benjamin L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bile; Cholestasis; Gallbladder; Ileum; Intestine; Lipid; Liver; Phoshatidic acid; Promoter

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ATPASE CLASS I TYPE 8B MEMBER 1; BILE SALT EXPORT PUMP PROTEIN; CARRIER PROTEIN; FARNESOID X RECEPTOR; PHOSPHOLIPASE D2; PROTEIN KINASE C ZETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INTRAHEPATIC CHOLESTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHO CELLS; CRICETINAE; CRICETULUS; GENE SILENCING; HEP G2 CELLS; HUMANS; PHOSPHOLIPASE D; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84872460682     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M030304     Document Type: Article

References (52)

1. Clayton, R. J., F. L. Iber, B. H. Ruebner, and V. A. McKusick. 1965. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. J. Pediatr. 67: 1025-1028.
2. Alissa, F. T., R. Jaffe, and B. L. Shneider. 2008. Update on progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 46: 241-252.
3. Bull, L. N., M. J. T. van Eijk, L. Pawlikowska, J. A. DeYoung, J. Juiun, M. Liao, L. W. J. Klomp, N. Lomri, R. Berger, B. F. Scharschmidt, et al. 1998. Identification of a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18: 219-224. (Pubitemid 28117258)
4. Pawlikowska, L., S. Strautnieks, I. Jankowska, P. Czubkowski, K. Emerick, A. Antoniou, C. Wanty, B. Fischler, E. Jacquemin, S. Wali, et al. 2010. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J. Hepatol. 53: 170-178.
5. Klomp, L. W., J. C. Vargas, S. W. van Mil, L. Pawlikowska, S. S. Strautnieks, M. J. van Eijk, J. A. Juijn, C. Pabon-Pena, L. B. Smith, J. A. DeYoung, et al. 2004. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology. 40: 27-38. (Pubitemid 38868920)
6. Folmer, D. E., V. A. van der Mark, K. S. Ho-Mok, R. P. Oude Elferink, and C. C. Paulusma. 2009. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology. 50: 1597-1605.
7. Frankenberg, T., T. Miloh, F. Y. Chen, M. Ananthanarayanan, A. Q. Sun, N. Balasubramaniyan, I. Arias, K. D. Setchell, F. J. Suchy, and B. L. Shneider. 2008. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology. 48: 1896-1905.
8. Stone, A., C. Chau, C. Eaton, E. Foran, M. Kapur, E. Prevatt, N. Belkin, D. Kerr, T. K. Kohlin, and P. Williamson. 2012. Biochemical characterization of P4-ATPase mutations identified in patients with progressive familial intrahepatic cholestasis. J. Biol. Chem. 287: 41139-41151
9. van Ooteghem, N. A., L. W. Klomp, G. P. van Berge-Henegouwen, and R. H. Houwen. 2002. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J. Hepatol. 36: 439-443.
10. Pawlikowska, L., A. Groen, E. F. Eppens, C. Kunne, R. Ottenhoff, N. Looije, A. S. Knisely, N. P. Killeen, L. N. Bull, R. P. Elferink, et al. 2004. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 13: 881-892. (Pubitemid 38515216)
11. Stapelbroek, J. M., T. A. Peters, D. H. van Beurden, J. H. Curfs, A. Joosten, A. J. Beynon, B. M. van Leeuwen, L. M. van der Velden, L. Bull, R. P. Oude Elferink, et al. 2009. ATP8B1 is essential for maintaining normal hearing. Proc. Natl. Acad. Sci. USA. 106: 9709-9714.
12. Ray, N. B., L. Durairaj, B. B. Chen, B. J. McVerry, A. J. Ryan, M. Donahoe, A. K. Waltenbaugh, C. P. O'Donnell, F. C. Henderson, C. A. Etscheidt, et al. 2010. Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat. Med. 16: 1120-1127.
13. Ujhazy, P., D. Ortiz, S. Misra, S. Li, J. Moseley, H. Jones, and I. Arias. 2001. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology. 34: 768-775. (Pubitemid 32928002)
14. Paulusma, C. C., D. E. Folmer, K. S. Ho-Mok, D. R. de Waart, P. M. Hilarius, A. J. Verhoeven, and R. P. Oude Elferink. 2008. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology. 47: 268-278. (Pubitemid 351171064)
15. Folmer, D. E., R. P. Elferink, and C. C. Paulusma. 2009. P4 ATPases - lipid flippases and their role in disease. Biochim. Biophys. Acta. 1791: 628-635.
16. Paulusma, C. C., A. Groen, C. Kunne, K. S. Ho-Mok, A. L. Spijkerboer, D. Rudi de Waart, F. J. Hoek, H. Vreeling, K. A. Hoeben, J. van Marle, et al. 2006. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology. 44: 195-204. (Pubitemid 44049152)
17. Cai, S. Y., S. Gautam, T. Nguyen, C. J. Soroka, C. Rahner, and J. L. Boyer. 2009. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology. 136: 1060-1069.
18. Paulusma, C. C., D. R. de Waart, C. Kunne, K. S. Mok, and R. P. Elferink. 2009. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J. Biol. Chem. 284: 9947-9954.
19. Groen, A., M. R. Romero, C. Kunne, S. J. Hoosdally, P. H. Dixon, C. Wooding, C. Williamson, J. Seppen, K. Van den Oever, K. S. Mok, et al. 2011. Complementary functions of the flippase ATP8B1 and the floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology 141: 1927-1937.e1-4.
20. Verhulst, P. M., L. M. van der Velden, V. Oorschot, E. E. van Faassen, J. Klumperman, R. H. Houwen, T. G. Pomorski, J. C. Holthuis, and L. W. Klomp. 2010. A flippase-independent function of ATP8B1, the protein affected in familial intrahepatic cholestasis type 1, is required for apical protein expression and microvillus formation in polarized epithelial cells. Hepatology. 51: 2049-2060.
21. Chen, F., M. Ananthanarayanan, S. Emre, E. Neimark, L. N. Bull, A. S. Knisely, S. S. Strautnieks, R. J. Thompson, M. S. Magid, R. Gordon, et al. 2004. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology. 126: 756-764. (Pubitemid 38298324)
22. Alvarez, L., P. Jara, E. Sanchez-Sabate, L. Hierro, J. Larrauri, M. C. Diaz, C. Camarena, A. De La Vega, E. Frauca, E. Lopez-Collazo, et al. 2004. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13: 2451-2460. (Pubitemid 39377849)
23. Martinez-Fernandez, P., L. Hierro, P. Jara, and L. Alvarez. 2009. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1119-G1129.
24. Koh, S., T. Takada, I. Kukuu, and H. Suzuki. 2009. FIC1-mediated stimulation of FXR activity is decreased with PFIC1 mutations in HepG2 cells. J. Gastroenterol. 44: 592-600.
25. Chen, F., E. Ellis, S. C. Strom, and B. L. Shneider. 2010. ATPase Class I Type 8B Member 1 and protein kinase C zeta induce the expression of the canalicular bile salt export pump in human hepatocytes. Pediatr. Res. 67: 183-187.
26. Kim, J. H., M. Ohba, P. G. Suh, and S. H. Ryu. 2005. Novel functions of the phospholipase D2-Phox homology domain in protein kinase Czeta activation. Mol. Cell. Biol. 25: 3194-3208. (Pubitemid 40464321)
27. Hanada, K., and R. E. Pagano. 1995. A Chinese hamster ovary cell mutant defective in the non-endocytic uptake of fluorescent analogs of phosphatidylserine: isolation using a cytosol acidification protocol. J. Cell Biol. 128: 793-804.
28. Ananthanarayanan, M., N. Balasubramanian, M. Makishima, D. Mangelsdorf, and F. Suchy. 2001. Human bile salt export pump promoter is transactivated by farsenoid X receptor/bile acid receptor. J. Biol. Chem. 276: 28857-28865.
29. Lopez, I., R. S. Arnold, and J. D. Lambeth. 1998. Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADPribosylation factor regulates hPLD2. J. Biol. Chem. 273: 12846-12852. (Pubitemid 28246841)
30. Harris, M. J., T. Kagawa, P. A. Dawson, and I. M. Arias. 2004. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells. J. Gastroenterol. Hepatol. 19: 819-825. (Pubitemid 38981406)
31. Frankenberg, T., A. Rao, F. Chen, J. Haywood, B. L. Shneider, and P. A. Dawson. 2006. Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G912-G922.
32. McConkey, M., H. Gillin, C. R. Webster, and M. S. Anwer. 2004. Cross-talk between protein kinases Czeta and B in cyclic AMP-mediated sodium taurocholate co-transporting polypeptide translocation in hepatocytes. J. Biol. Chem. 279: 20882-20888. (Pubitemid 38656485)
33. Muscella, A., C. Storelli, and S. Marsigliante. 2005. Atypical PKC-zeta and PKC-iota mediate opposing effects on MCF-7 Na+/K+ATPase activity. J. Cell. Physiol. 205: 278-285. (Pubitemid 41428911)
34. Su, W., O. Yeku, S. Olepu, A. Genna, J. S. Park, H. Ren, G. Du, M. H. Gelb, A. J. Morris, and M. A. Frohman. 2009. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 75: 437-446.
35. Chen, F., L. Ma, N. Al-Ansari, and B. Shneider. 2001. The role of AP-1 in the transcriptional regulation of the rat apical sodium-dependent bile acid transporter. J. Biol. Chem. 276: 38703-38714.
36. Malter, J. S. 1989. Identification of an AUUUA-specific messenger RNA binding protein. Science. 246: 664-666. (Pubitemid 19283358)
37. Coppola, C. P., J. R. Gosche, M. Arrese, B. Ancowitz, J. Madsen, J. Vanderhoof, and B. L. Shneider. 1998. Molecular analysis of the adaptive response of intestinal bile acid transport after ileal resection. Gastroenterology. 115: 1172-1178. (Pubitemid 28485608)
38. Shneider, B. L., P. A. Dawson, D. M. Christie, W. Hardikar, M. H. Wong, and F. J. Suchy. 1995. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J. Clin. Invest. 95: 745-754.
39. Goodwin, B., S. Jones, R. Price, M. Watson, D. McKee, L. Moore, C. Galardi, J. Wilson, M. Lewis, M. Roth, et al. 2000. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell. 6: 517-526.
40. Lu, T. T., M. Makishima, J. J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, and D. J. Mangelsdorf. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 6: 507-515.
41. Lambert, G., M. J. Amar, G. Guo, H. B. Brewer, Jr., F. J. Gonzalez, and C. J. Sinal. 2003. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278: 2563-2570. (Pubitemid 36801334)
42. Siebold, L., F. Chen, T. Miloh, and B. Shneider. 2011. 4-Phenylbutyrate and subenroylanilide hydroxomic acid enhance FXR mediated signaling by wild type and mutant FIC1 proteins-potential pharmacologic approaches to the treatment of Byler Disease and Benign Recurrent Intrahepatic Cholestasis. Hepatology. 54: 88A.
43. Jang, J. H., C. S. Lee, D. Hwang, and S. H. Ryu. 2012. Understanding of the roles of phospholipase D and phosphatidic acid through their binding partners. Prog. Lipid Res. 51: 71-81.
44. Selvy, P. E., R. R. Lavieri, C. W. Lindsley, and H. A. Brown. 2011. Phospholipase D: enzymology, functionality, and chemical modulation. Chem. Rev. 111: 6064-6119.
45. Huang, P., and M. A. Frohman. 2007. The potential for phospholipase D as a new therapeutic target. Expert Opin. Ther. Targets. 11: 707-716. (Pubitemid 46730084)
46. McDermott, M., M. J. Wakelam, and A. J. Morris. 2004. Phospholipase D. Biochem. Cell Biol. 82: 225-253. (Pubitemid 38580885)
47. Hancock, J. F. 2007. PA promoted to manager. Nat. Cell Biol. 9: 615-617. (Pubitemid 47214719)
48. Colley, W. C., T. C. Sung, R. Roll, J. Jenco, S. M. Hammond, Y. Altshuller, D. Bar-Sagi, A. J. Morris, and M. A. Frohman. 1997. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 7: 191-201. (Pubitemid 27164725)
49. Meier, K. E., T. C. Gibbs, S. M. Knoepp, and K. M. Ella. 1999. Expression of phospholipase D isoforms in mammalian cells. Biochim. Biophys. Acta. 1439: 199-213. (Pubitemid 29333132)
50. Kim, H., J. Lee, S. Kim, M. K. Shin, S. Min do, and T. Shin. 2007. Differential expression of phospholipases D1 and D2 in mouse tissues. Cell Biol. Int. 31: 148-155. (Pubitemid 46201910)
51. Lan, W., and L. Tong. 2012. Focus on molecules: phospholipase D. Exp. Eye Res. 103: 121-122.
52. Limatola, C., D. Schaap, W. H. Moolenaar, and W. J. van Blitterswijk. 1994. Phosphatidic acid activation of protein kinase C-zeta overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids. Biochem. J. 304: 1001-1008.